Robert Kleinman and colleagues examine the efficacy and safety of reducing supervised dosing of sublingual buprenorphine-naloxone for opioid use disorder
No takes yet. Share an insight, caveat, or question.
Kleinman et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: